The Experts below are selected from a list of 84366 Experts worldwide ranked by ideXlab platform

Felipe A Calvo - One of the best experts on this subject based on the ideXlab platform.

  • estro iort task force acrop recommendations for intraoperative radiation therapy in borderline resected pancreatic cancer
    Clinical and Translational Radiation Oncology, 2020
    Co-Authors: Frank W Hensley, Felipe A Calvo, Philip Poortmans, Falk Roeder, Robert Krempien, Jose Manuel Asencio, Marco Krengli
    Abstract:

    Abstract Radiation therapy (RT) is a valuable component of multimodal Treatment for localized pancreatic cancer. Intraoperative radiation therapy (IORT) is a very precise RT modality to intensify the irradiation effect for cancer involving upper abdominal structures and organs, generally delivered with electrons (IOERT). Unresectable, borderline and resectable disease categories benefit from dose-escalated chemoradiation strategies in the context of active systemic therapy and potential radical surgery. Prolonged Preoperative Treatment may act as a filter for selecting patients with occult resistant metastatic disease. Encouraging survival rates have been documented in patients treated with Preoperative chemoradiation followed by radical surgery and IOERT (>20 months median survival, >35% survival at 3 years). Intensive Preoperative Treatment, including induction chemotherapy followed by chemoradiation and an IOERT boost, appears to prolong long-term survival within the subset of patients who remain relapse-free for>2 years (>30 months median survival; >40% survival at 3 years). Improvement of local control through higher RT doses has an impact on the survival of patients with a lower tendency towards disease spread. IOERT is a well-accepted approach in the clinical scenario (maturity and reproducibility of results), and extremely accurate in terms of dose-deposition characteristics and normal tissue sparing. The technique can be adapted to systemic therapy and surgical progress. International guidelines (National Comprehensive Cancer Network or NCCN guidelines) currently recommend use of IOERT in cases of close surgical margins and residual disease. We hereby report the ESTRO/ACROP recommendations for performing IOERT in borderline-resectable pancreatic cancer.

H Boot - One of the best experts on this subject based on the ideXlab platform.

  • critics ii a multicentre randomised phase ii trial of neo adjuvant chemotherapy followed by surgery versus neo adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
    BMC Cancer, 2018
    Co-Authors: Astrid E Slagter, Edwin P M Jansen, Hanneke W M Van Laarhoven, Johanna W Van Sandick, Nicole C T Van Grieken, Karolina Sikorska, Annemieke Cats, Pietje Mullertimmermans, Maarten C C M Hulshof, H Boot
    Abstract:

    Although radical surgery remains the cornerstone of cure in resectable gastric cancer, survival remains poor. Current evidence-based (neo)adjuvant strategies have shown to improve outcome, including perioperative chemotherapy, postoperative chemoradiotherapy and postoperative chemotherapy. However, these regimens suffer from poor patient compliance, particularly in the postoperative phase of Treatment. The CRITICS-II trial aims to optimize Preoperative Treatment by comparing three Treatment regimens: (1) chemotherapy, (2) chemotherapy followed by chemoradiotherapy and (3) chemoradiotherapy. In this multicentre phase II non-comparative study, patients with clinical stage IB-IIIC (TNM 8th edition) resectable gastric adenocarcinoma are randomised between: (1) 4 cycles of docetaxel+oxaliplatin+capecitabine (DOC), (2) 2 cycles of DOC followed by chemoradiotherapy (45Gy in combination with weekly paclitaxel and carboplatin) or (3) chemoradiotherapy. Primary endpoint is event-free survival, 1 year after randomisation (events are local and/or regional recurrence or progression, distant recurrence, or death from any cause). Secondary endpoints include: toxicity, surgical outcomes, percentage radical (R0) resections, pathological tumour response, disease recurrence, overall survival, and health related quality of life. Exploratory endpoints include translational studies on predictive and prognostic biomarkers. The aim of this study is to select the most promising among three Preoperative Treatment arms in patients with resectable gastric adenocarcinoma. This Treatment regimen will subsequently be compared with the standard therapy in a phase III trial. clinicaltrials.gov NCT02931890 ; registered 13 October 2016. Date of first enrolment: 21 December 2017.

Marco Krengli - One of the best experts on this subject based on the ideXlab platform.

  • estro iort task force acrop recommendations for intraoperative radiation therapy in borderline resected pancreatic cancer
    Clinical and Translational Radiation Oncology, 2020
    Co-Authors: Frank W Hensley, Felipe A Calvo, Philip Poortmans, Falk Roeder, Robert Krempien, Jose Manuel Asencio, Marco Krengli
    Abstract:

    Abstract Radiation therapy (RT) is a valuable component of multimodal Treatment for localized pancreatic cancer. Intraoperative radiation therapy (IORT) is a very precise RT modality to intensify the irradiation effect for cancer involving upper abdominal structures and organs, generally delivered with electrons (IOERT). Unresectable, borderline and resectable disease categories benefit from dose-escalated chemoradiation strategies in the context of active systemic therapy and potential radical surgery. Prolonged Preoperative Treatment may act as a filter for selecting patients with occult resistant metastatic disease. Encouraging survival rates have been documented in patients treated with Preoperative chemoradiation followed by radical surgery and IOERT (>20 months median survival, >35% survival at 3 years). Intensive Preoperative Treatment, including induction chemotherapy followed by chemoradiation and an IOERT boost, appears to prolong long-term survival within the subset of patients who remain relapse-free for>2 years (>30 months median survival; >40% survival at 3 years). Improvement of local control through higher RT doses has an impact on the survival of patients with a lower tendency towards disease spread. IOERT is a well-accepted approach in the clinical scenario (maturity and reproducibility of results), and extremely accurate in terms of dose-deposition characteristics and normal tissue sparing. The technique can be adapted to systemic therapy and surgical progress. International guidelines (National Comprehensive Cancer Network or NCCN guidelines) currently recommend use of IOERT in cases of close surgical margins and residual disease. We hereby report the ESTRO/ACROP recommendations for performing IOERT in borderline-resectable pancreatic cancer.

Falk Roeder - One of the best experts on this subject based on the ideXlab platform.

  • estro iort task force acrop recommendations for intraoperative radiation therapy in borderline resected pancreatic cancer
    Clinical and Translational Radiation Oncology, 2020
    Co-Authors: Frank W Hensley, Felipe A Calvo, Philip Poortmans, Falk Roeder, Robert Krempien, Jose Manuel Asencio, Marco Krengli
    Abstract:

    Abstract Radiation therapy (RT) is a valuable component of multimodal Treatment for localized pancreatic cancer. Intraoperative radiation therapy (IORT) is a very precise RT modality to intensify the irradiation effect for cancer involving upper abdominal structures and organs, generally delivered with electrons (IOERT). Unresectable, borderline and resectable disease categories benefit from dose-escalated chemoradiation strategies in the context of active systemic therapy and potential radical surgery. Prolonged Preoperative Treatment may act as a filter for selecting patients with occult resistant metastatic disease. Encouraging survival rates have been documented in patients treated with Preoperative chemoradiation followed by radical surgery and IOERT (>20 months median survival, >35% survival at 3 years). Intensive Preoperative Treatment, including induction chemotherapy followed by chemoradiation and an IOERT boost, appears to prolong long-term survival within the subset of patients who remain relapse-free for>2 years (>30 months median survival; >40% survival at 3 years). Improvement of local control through higher RT doses has an impact on the survival of patients with a lower tendency towards disease spread. IOERT is a well-accepted approach in the clinical scenario (maturity and reproducibility of results), and extremely accurate in terms of dose-deposition characteristics and normal tissue sparing. The technique can be adapted to systemic therapy and surgical progress. International guidelines (National Comprehensive Cancer Network or NCCN guidelines) currently recommend use of IOERT in cases of close surgical margins and residual disease. We hereby report the ESTRO/ACROP recommendations for performing IOERT in borderline-resectable pancreatic cancer.

Astrid E Slagter - One of the best experts on this subject based on the ideXlab platform.

  • critics ii a multicentre randomised phase ii trial of neo adjuvant chemotherapy followed by surgery versus neo adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
    BMC Cancer, 2018
    Co-Authors: Astrid E Slagter, Edwin P M Jansen, Hanneke W M Van Laarhoven, Johanna W Van Sandick, Nicole C T Van Grieken, Karolina Sikorska, Annemieke Cats, Pietje Mullertimmermans, Maarten C C M Hulshof, H Boot
    Abstract:

    Although radical surgery remains the cornerstone of cure in resectable gastric cancer, survival remains poor. Current evidence-based (neo)adjuvant strategies have shown to improve outcome, including perioperative chemotherapy, postoperative chemoradiotherapy and postoperative chemotherapy. However, these regimens suffer from poor patient compliance, particularly in the postoperative phase of Treatment. The CRITICS-II trial aims to optimize Preoperative Treatment by comparing three Treatment regimens: (1) chemotherapy, (2) chemotherapy followed by chemoradiotherapy and (3) chemoradiotherapy. In this multicentre phase II non-comparative study, patients with clinical stage IB-IIIC (TNM 8th edition) resectable gastric adenocarcinoma are randomised between: (1) 4 cycles of docetaxel+oxaliplatin+capecitabine (DOC), (2) 2 cycles of DOC followed by chemoradiotherapy (45Gy in combination with weekly paclitaxel and carboplatin) or (3) chemoradiotherapy. Primary endpoint is event-free survival, 1 year after randomisation (events are local and/or regional recurrence or progression, distant recurrence, or death from any cause). Secondary endpoints include: toxicity, surgical outcomes, percentage radical (R0) resections, pathological tumour response, disease recurrence, overall survival, and health related quality of life. Exploratory endpoints include translational studies on predictive and prognostic biomarkers. The aim of this study is to select the most promising among three Preoperative Treatment arms in patients with resectable gastric adenocarcinoma. This Treatment regimen will subsequently be compared with the standard therapy in a phase III trial. clinicaltrials.gov NCT02931890 ; registered 13 October 2016. Date of first enrolment: 21 December 2017.